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Abstract
Background: Myocardial perfusion scintigraphy (MPS) is a well-established diagnostic tool. 
The sensitivity and specificity of single photon emission computed tomography (SPECT) MPS 
to detect significant coronary lesion were 86% and 74%, respectively. The aim of this study was 
to examine the role of serum copeptin in evaluation of MPS.
Methods: Sixty-two consecutive patients underwent both SPECT MPS using 99mTc-sestamibi 
and transthoracic echocardiography were enrolled prospectively. Age, gender, height, weight, 
presence of cardiovascular risk factors were recorded. Exercise treadmill test (ETT) with 
modified Bruce protocol was used to induce coronary ischemia during MPS. While performing 
MPS, blood samples for serum copeptin level were drawn three times at pre-exercise, at the peak 
of ETT, and 6 h after ETT, respectively. The patients were enrolled into three groups according 
to MPS results (normal, equivocal and ischemia).
Results: The study included 62 patients (23 with normal, 20 with equivocal, 19 with ischemia 
on MPS). Pre-, peak-, and post-exercise B-type natriuretic peptide and troponin I values were 
similar across the groups (p > 0.05 for all comparisons). Serum copeptin values for pre- and 
peak-exercise were similar among all groups (p = 0.883 and p = 0.089). Post-exercise copeptin 
values of the normal and equivocal groups were similar (p = 0.661, z = –0.438) while that of the 
ischemia group was significantly higher than both the normal (p < 0.001) and equivocal group 
(p < 0.001).
Conclusions: Serum copeptin was found to be increasing significantly in case of ischemia on 
MPS. It may be used in differentiation of equivocal results from false positive results. (Cardiol J  
2016; 23, 1: 71–77)
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Introduction
Myocardial perfusion scintigraphy (MPS) is 
a well-established diagnostic tool in the differentiation 
of new-onset chest pain of patients with or without 
previous coronary artery disease (CAD). MPS is 
especially helpful for the patients with basal electro-
cardiographic (ECG) changes as left bundle branch 
block, left ventricle (LV) hypertrophy, pre-excitation 
and with non-diagnostic exercise ECG test results, 
or for subjects unable to exercise due to orthopedic 
or neurological problems [1].
The sensitivity and specificity of single photon 
emission computed tomography (SPECT) MPS 
to detect significant coronary lesion (defined as 
coronary stenosis of more than 50%) were 86% 
and 74%, accordingly [2]. A false negative result 
can be obtained in the SPECT MPS due to balanced 
multiple vessel disease. Thus, nearly 13–15% of 
patients with left main disease can have normal 
perfusion scintigraphy due to balanced ischemia 
in multivessel CAD [3, 4]. Other disadvantages 
in MPS are equivocal results due to attenuation 
artifacts, patient positional movement during the 
test, or incorrectly applied technical analyses. Also 
incorrectly performed technical analyses such as 
multidetector misallignment, incorrectly designed 
bull’s eye reconstruction, presence of non-uniform 
flood fields can lead to false positive or equivocal 
results [5]. Guided by these results, physicians 
can be forced to apply invasive diagnostic tests. 
In such false positive cases, application of gated 
studies, attenuation correction algorithms, and 
prone imaging technique can promote diagnostic 
accuracy but cannot be enough to solve the problem 
all the time [6–8].
Copeptin, the C-terminal part of the vasopres-
sin prohormone, is released stoichiometrically with 
arginine-vasopressin from the neurohypophysis 
and seems to reflect the individual endogenous 
stress level and also the mortality risk in coronary 
events [9]. As the endogenous stress is already 
present at the onset of coronary ischemia, copeptin 
appears to be able to detect coronary ischemia very 
early following symptom onset, even when cardiac 
troponin is still negative [10]. The role of copeptin 
in evaluation of MPS results has not been studied 
extensively.
The aim of our study was to search role of 
serum copeptin in further evaluation of different 
myocardial perfusion scintigraphy results (normal 
scan, equivocal, and ischemia) among patients in 
suspect of CAD.
Methods
Subjects
We prospectively studied 62 consecutive pa-
tients referred to the Cardiology Department with 
chest pain in suspicion of CAD. The patients un-
derwent both SPECT MPS using technetium-99m-
sestamibi (99mTc-sestamibi) and transthoracic echo-
cardiography between January 2014 and September 
2014. Subjects aged 18–65 years old were included 
in the study.
Patients with previous CAD, acute coronary 
syndrome, angina pectoris of Canadian Cardiology 
Society class III or IV angina, peripheric vascular dis-
ease, chronic kidney disease (creatinine > 1.4 mg/ 
/dL), advanced liver disease, stroke, cancer, in-
fection, hyper- or hypothyroidism, symptomatic 
congestive heart failure, left ventricular ejection 
fraction (LVEF) less than 50%, any congenital heart 
disease were excluded. In addition, patients with 
history of myocardial infarction based on echocar-
diography and ECG findings or coronary artery 
bypass grafting were also ruled out.
The following data were also obtained: age, 
gender, height, weight, presence of cardiovascular 
risk factors. Cardiovascular risk factors were de-
termined according to the following criteria: posi-
tive family history for CAD (presence of CAD in 
first-degree family members, male < 55 years and/ 
/or female < 65 years), cigarette smoking (current 
smoking or smoking in the last 2 years), hyper-
tension (the last 3 blood pressure measurements 
> 140/90 mm Hg or treatment with antihyperten-
sive medication within the last 6 months), hyper-
lipidemia (current usage of cholesterol-lowering 
medication).
Body mass index (BMI) was defined according 
to the World Health Organization criteria. Patients 
were classified as normal weight (BMI 18.5– 
–24.9 kg/m2), overweight (BMI 25.0–29.9 kg/m2), 
obese class I (BMI 30.0–34.9 kg/m2), obese class II 
(BMI 35.0–39.9 kg/m2) or obese class III (BMI 
40 kg/m2 or more).
The ethical approval and informed consent 
from each patient was provided for the study and 
the investigation was performed in accordance 
with the principles outlined in the Declaration of 
Helsinki.
Rest/stress myocardial perfusion  
scintigraphy protocol
In this study, we used a same-day stress/rest 
protocol, with the stress test performed in the 
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morning between 08:00–10:00 a.m. and the rest 
test performed on same day 6 h after the stress 
test. All subjects underwent exercise treadmill 
test (ETT) with modified Bruce protocol to induce 
coronary ischemia. End points of exercise testing 
were physical exhaustion, severe angina, sustained 
ventricular arrhythmia or exertional hypotension. 
At near-maximal exercise, 99mTc-sestamibi was 
injected and exercise was continued for two ad-
ditional 2 min after injection. The patients who 
could not achieve at least 6-min exercise and 85% 
of targeted heart rate (220 min age in years) were 
excluded from the study.
SPECT acquisition protocol
The SPECT data were acquired with Gated 
technique using the double-head SPECT gamma-
camera system (Philips Medical Systems Bright-
view Gamma Diagnostic, Holland) equipped with 
a high-resolution low-energy collimator. A total 
of 32 projections (35 s/projection) were obtained 
over a 180° circular orbit, at the 20% energy window 
which centered 140 keV for gamma emission of tech-
netium-99m. Myocardial images were projected into 
tomographic slices in the short axis, verticallong 
axis and horizontal-long axis views. 4D-M SPECT 
software was used for semiquantitative analysis of 
data. The SPECT images were reconstructed by 
filtered back projection method using a Butterworth 
filter (order 5; cut-off frequency 0.50).
Image interpretation
The perfusion images were evaluated inde-
pendently by two experienced nuclear medicine 
physicians without clinical data. Disagreement 
was solved by consensus. The myocardium was 
divided into 17 segments for semiquantitative 
analysis, following the American Society of Nuclear 
Cardiology, the American College of Cardiology and 
the American Heart Association guidelines [11]. 
A scale of 0–4 was used for grading wall motion: 
(0 — normal, 1 — mildly hypokinetic, 2 — hypoki-
netic, 3 — akinetic, and 4 — dyskinetic) by automatic 
scores for each of the segments [12]. Abnormal 
motion was defined as a score of > 2. According 
to the test results, patients were classified into 
three groups. Normal group was the patients with 
normal Gated SPECT MPS scans. Equivocal group 
included indeterminate scan results that patients 
with slight perfusion and/or mildly hypokinetic 
wall motion. Third group was the ischemia group 
including patients with apparent abnormal perfu-
sion and/or wall motion findings in any segment of 
LV myocardium at stress.
Echocardiography protocol
Two-dimensional (2D), M-mode, pulsed Dop-
pler and tissue Doppler echocardiography were per-
formed on an ultrasound machine (Presound alpha 7, 
IPF 1701 Model, 2009; Hitachi Aloka Medical, 
Ltd. Tokyo, Japan) with a 2.5-MHz transducer by 
cardiologist blinded to the study before perform-
ing MPS. Standard 2D measurements (LV diastolic 
and systolic dimension, ventricular septum and 
posterior wall thickness, left atrial diameter, LVEF) 
were obtained as recommended by the American 
Society of Echocardiography [13]. Mitral annular 
velocities were obtained by Doppler tissue imaging 
using the pulsed-wave mode. Early diastolic mitral 
annular (Em), late diastolic (Am) and systolic ve-
locities (Sm) of the mitral annulus were measured 
from the apical 4-chamber view with a 2- to 5-mm 
sample volume placed at the lateral edge of the 
mitral annulus. All measurements were carried 
out at expirium.
Biochemical measurements
A specimen of venous blood was drawn before 
(pre-exercise), 1 min after peak exercise (peak-
-exercise) and 6 h after exercise (post-exercise) in 
the seated position from a catheter inserted into 
the antecubital vein. These samples were collected 
in plastic tubes containing ethylenediaminetet-
raacetic acid (EDTA). They were placed on ice 
and then centrifuged at 3,000 g; and plasma was 
frozen at –80°C until assay. Commercial enzyme-
linked immunosorbent assay (ELISA) kits were 
used to measure Human B-type natriuretic peptide 
(Ray Biotech, Inc. USA), cardiac troponin I (cTnI) 
(Ray Biotech, Inc. USA), human copeptin (ELAB-
SCIENCE, Wuhan, Hubei Province, China). The 
laboratory technician who measured copeptin was 
at a different place and blinded to the data of the pa-
tients. All other parameters were measured using 
standard laboratory methods in the core laboratory. 
Serum levels of high density lipoprotein (HDL), 
low density lipoprotein (LDL), total cholesterol, 
triglyceride (TG), creatinine, thyroid stimulating 
hormone (TSH) and fasting blood glucose (FBG) 
were measured for all patients accordingly.
Statistical analysis
Statistical analyses were performed using the 
SPSS software version 18. Continuous variables 
are presented as mean ± standard deviation and 
categorical variables are presented as frequencies 
(%). Except hemoglobin, creatinine, total cho-
lesterol, and LDL, all other continuous variables 
did not have normal distribution according to 
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Kolmogorov-Smirnov test. Categorical variables 
were compared using the c2 test. Spearman simple 
correlation analyses were performed to deter-
mine the association between continuous param-
eters accordingly while Mann-Whitney U test and 
Kruskal-Wallis test were used to compare groups 
accordingly. Wilcoxon rank-sum test was used to 
compare pre-, peak- and post-exercise biochemical 
values within the groups. To find diagnostic cut-off 
value of copeptin for differentiation of patients with 
normal scan from patients with ischemia, a receiver 
operating characteristic (ROC) curve analysis was 
constructed, and the area under the curve (AUC) 
was reported, which is considered representative 
of the discriminative ability of the variable cut-off. 
Sensitivity and specificity values of the best cut-
off variables were determined using ROC curve 
analysis. A p value of less than 0.05 was considered 
to show statistically significant result.
Results
Sixty-two subjects were included in the study 
and the data of the patients undergone to rest/ 
/treadmill stress myocardial perfusion SPECT were 
expressed in Table 1. At rest/treadmill myocardial 
perfusion SPECT, an ischemia was induced in 
19 (31%) patients, while 23 (37%) patients had normal 
MPS results and 20 (32%) patients with equivocal 
test results. All subjects succeeded at least 6-min 
exercise and 85% of targeted heart rate. Endpoint 
of the exercise test was physical exhaustion for 
all patients except 1 patient who described angina 
without relevant ECG changes. The data related to 
treadmill test findings were summarized in Table 1. 
All groups had statistically similar LVEF, left atrial 
diameter and Em/Am ratios. Laboratory findings of 
serum FBG, TSH, creatinine and fasting lipid profile 
were statistically similar among the groups (Table 2).
Subjects in the equivocal group were further 
evaluated in suspect of CAD accordingly. We found 
that 11 patients had normal coronary arteries accord-
ing to result of conventional coronary angiography 
(CAG) and 4 patients had zero-score coronary com-
puted tomographic angiography result, 3 patients had 
non-obstructive and 2 patients with obstructive CAD 
upon CAG or computed tomography examinations.
In the ischemia group, 6 (32%) patients had 
apparent abnormal perfusion and/or wall motion 
findings at inferior wall, 7 (37%) patients at infe-
rolateral, 5 (26%) patients at anterior wall, 1 (5%) 
patients at apical part of the LV. 89% of subjects 
with ischemia on MPS (n = 18) revealed obstruc-
tive CAD according to the CAG results. Two sub-
jects had non-obstructive CAD.
Median serum copeptin levels increased sig-
nificantly with exercise in the all subjects from 
7.8 (IQR 7.2–8.1) to 9.7 (IQR 8.7–10.6) pmol/L 
Table 1. Demographic and clinical data of the subjects.
Normal group  
(n = 23)
Equivocal group  
(n = 20)
Ischemia group  
(n = 19)
P
Age [year] 52 ± 12 48 ± 10 54 ± 10 0.161
Gender (F/M) 17/6 (74/26)  12/8 (60/40) 11/8 (58/42)  0.489
Height [cm] 162 ± 4 161 ± 4 164 ± 3 0.100
Weight [kg] 71 ± 3 71 ± 4 72 ± 6 0.511
Body mass index 27.1 ± 1.7 27.5 ± 1.6 27.0 ± 2.2 0.445
Diabetes mellitus 7 (30%)  4 (205) 3 (16%) 0.499
Hypertension 8 (35%) 2 (10%) 6 (32%) 0.142
Cigarette smoking 4 (17%) 6 (30%) 5 (26%) 0.608
Family history of premature CAD 5 (22%) 3 (15%) 4 (215%) 0.834
Hyperlipidemia 1 (4%) 0 (0%) 3 (15%) 0.117
Systolic BP [mm Hg] 120 ± 11 121 ± 10 127 ± 11 0.169
Diastolic BP [mm Hg] 76 ± 4 77 ± 3 75 ± 4 0.279
Exercise duration [s] 600 ± 140 651 ± 124 616 ± 155 0.553
Rate pressure product at peak  
exercise [mm Hg/min]
25,805 ± 4,413 25,502 ± 5,101 27,147 ± 4,775 0.467
Maximal workload [MET] 10.8 ± 2.11 11.2 ± 2.0 11.0 ± 2.2 0.847
BP — blood pressure; CAD — coronary artery disease; F — female; M — male; MET — metabolic equivalent
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(p < 0.001). However, median serum copeptin 
level of patients with ischemia on MPS increased 
significantly with exercise from 7.8 (IQR 7.2–8.4) to 
10.9 (IQR 8.8–12.1) pmol/L (p < 0.001) and that of 
patients with normal result on MPS from 7.7 (IQR 
7.0–8.1) to 9.4 (IQR 8.2–10.3) pmol/L (p < 0.005). 
Similarly, serum copeptin level of patients with 
equivocal test results on MPS increased signifi-
cantly with exercise from 7.8 (IQR 7.4–8.0) to 9.6 
(IQR 8.7–10.1) pmol/L (p < 0.005).
Median serum post-exercise copeptin levels of 
patients with normal and equivocal test results on 
MPS were returned to pre-exercise levels while that 
of patients with ischemia on MPS increased more 
compared to their pre-exercise levels (Table 3). 
Cardiac troponin and serum B-type natriuretic 
peptide levels did not show any significant change 
with exercise.
Average pre-exercise copeptin level did not 
differ significantly between man and women (7.7 ± 
± 0.6 and 7.7 ± 0.8 pmol/L, respectively, p = 0.622). 
Additionally, we did not find any statistical co-
rrelation of pre-exercise copeptin level and age 
(r = –0.208, p = 0.105).
ROC curve analysis was conducted to find cut-
off value for serum copeptin to detect myocardial 
ischemia. Cut-off value for post-exercise serum 
copeptin was 9.83 pmol/L with sensitivity of 94.7% 
and specificity of 73.9% (AUC 0.918 with 95% CI 
0.837–0.999 and p < 0.001). ROC curve analysis 
was also performed for Dcopeptin (the differ-
ence of post-exercise copeptin from pre-exercise 
copeptin) to detect myocardial ischemia. Cut-off 
value for Dcopeptin was found to be 1.85 pmol/L 
with sensitivity of 89.5% and specificity of 73.9% 
(AUC 0.924 with 95% CI 0.850–0.999, p < 0.001).
Table 3. Echocardiographic and biochemical measurements of the subjects.
Normal group  
(n = 23)
Equivocal group  
(n = 20)
Ischemia group  
(n = 19)
P
Left ventricular ejection fraction [%] 62 ± 3 64 ± 3 62 ± 2 0.061
Left atrium diameter [mm] 37 ± 3 37 ± 2 39 ± 2 0.070
Mitral annulus TDI Em/Am 1.48 ± 0.78 1.66 ± 0.60 1.34 ± 0.66 0.364
Pre-exercise BNP [pg/mL] 10.0 ± 1.8 9.4 ± 1.6 10.3 ± 3.1 0.467
Peak-exercise BNP [pg/mL] 14.5 ± 5.5 11.3 ± 1.9 12.5 ± 3.8 0.078
Post-exercise BNP [pg/mL] 9.0 ± 1.3 8.3 ± 1.2 9.2 ± 2.4 0.330
Pre-exercise troponin I [ng/mL] 0.064 ± 0.008 0.064 ± 0.007 0.062 ± 0.005 0.712
Peak-exercise troponin I [ng/mL] 0.085 ± 0.012 0.082 ± 0.014 0.084 ± 0.011 0.884
Post-exercise troponin I [ng/mL] 0.070 ± 0.016 0.066 ± 0.009 0.074 ± 0.016 0.296
Pre-exercise copeptin [pmol/L] 7.7 ± 0.7 7.7 ± 0.6 7.8 ± 0.7 0.883
Peak-exercise copeptin [pmol/L] 9.2 ± 1.5 9.5 ± 1.8 10.5 ± 1.8 0.089
Post-exercise copeptin [pmol/L] 7.7 ± 2.7 7.8 ± 2.5 12.2 ± 2.0 0.000
DCopeptin [pmol/L] 0.02 ± 2.55 0.16 ± 2.30 4.40 ± 2.02 0.000
BNP — B-type natriuretic peptide; TDI — tissue Doppler imaging
Table 2. Laboratory findings of the subjects.
Normal group  
(n = 23)
Equivocal group  
(n = 20)
Ischemia group  
(n = 19)
P
Fasting blood glucose [mg/dL] 110 ± 29 108 ± 34 112 ± 35 0.425
Creatinine [mg/dL] 0.82 ± 0.19 0.86 ± 0.12 0.86 ± 0.13 0.334
Total cholesterol [mg/dL] 193 ± 24 189 ± 24 194 ± 26 0.515
Triglyceride [mg/dL] 155 ± 60 161 ± 57 164 ± 56 0.724
High density lipoprotein [mg/dL] 47 ± 8 43 ± 10 42 ± 6 0.161
Low density lipoprotein [mg/dL] 116 ± 22 115 ± 17 121 ± 20 0.416
Thyroid stimulating hormone [IU/L] 1.75 ± 0.74 1.85 ± 1.28 1.54 ± 0.75 0.621
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Discussion
This study prospectively explored the role 
of copeptin in evaluation of myocardial perfusion 
test results among patients referred for treadmill 
exercise myocardial perfusion SPECT. We can 
summarize our findings in 4 major headings. Firstly, 
serum copeptin levels increase significantly with 
exercise, independent of myocardial perfusion re-
sults. Secondly, response of patients with normal or 
equivocal perfusion images to exercise was similar 
in respect to serum pre-, peak-, and post-exercise 
copeptin levels. Thirdly, patients with ischemia on 
MPS had significantly higher post-exercise copeptin 
level compared to the others. Fourth, post-exercise 
serum copeptin level and Dcopeptin (the difference 
between pre- and post-exercise) does seem benefi-
cial biomarker in detection of myocardial ischemia 
on MPS rather than the difference between pre- and 
peak-exercise copeptin levels.
Vasopressin, also known as antidiuretic hor-
mone, is a nanopeptide produced in the hypo-
thalamus and secreted into the circulation from the 
neurohypophysis to maintain osmolarity and water 
homeostasis [14]. Copeptin is the C-terminal part of 
the vasopressin prohormone. Opposite to vasopres-
sin which has a half-life of 10–20 min, copeptin can 
be detected in the circulation for days [15]. Serum 
vasopressin level has been shown to be increased 
in heart failure, septic shock, myocardial infarction 
and other endogenous stress conditions [16–18].
Results from our study were consistent with 
previous studies searching response of vasopres-
sin and copeptin to exercise. It was reported that 
serum copeptin was increased in response to ex-
ercise, proportional to increment in workload [15, 
19]. In our study, exercise statistically elevated 
serum copeptin levels at peak exercise in all sub-
jects irrespective of myocardial perfusion results. 
This finding was in concordant with the literature 
reporting increment of vasopressin in proportion 
to a 6-min walk test result among subjects with 
known CAD [20]. Mockel and Searle [21] also 
confirmed this finding. They found that serum 
copeptin level increased significantly in subjects 
with both normal and ischemia on MPS. However, 
both groups had similar peak-baseline copeptin 
difference during exercise [21].
In our study, we also found that the subjects 
with normal and ischemic MPS result had similar 
peak-baseline copeptin changes (1.5 ± 1.7 vs. 
2.8 ± 1.9 pmol/L, p = 0.063). In addition to the 
study by Mockel and Searle [21], we followed the 
subjects and measured serum copeptin level 6 h 
after the treadmill test. We found that post-exercise 
copeptin level of subjects with ischemia on MPS had 
significantly higher than the others, while values 
of subjects with normal and equivocal test results 
returned to pre-exercise levels. In parallel to these 
findings, it was revealed that Dcopeptin value of 
ischemia group was significantly higher than that 
of normal and equivocal groups. We concluded that 
additional endogenous stress due to coronary isch-
emia led further increment in post-exercise copeptin 
levels. This finding can be very beneficial especially 
in false negative cases such as normal perfusion 
scintigraphy due to balanced ischemia in multivessel 
CAD [3, 4]. Confirmation of increased copeptin level 
at post-exercise can guide physician accordingly to 
apply further diagnostic interventions.
Copeptin has been shown to be a helpful 
marker in detection of acute myocardial infarction 
and prognostic marker in heart failure with low 
ejection fraction [21, 22]. There have been studies 
searching the use of copeptin in differentiation of 
exercise-induced ischemia on MPS but our study 
investigated for the first time the behavior of 
copeptin both during and after the exercise [23]. 
According to our results, neither pre-exercise nor 
peak-exercise copeptin levels was statistically 
related to ischemia on MPS but post-exercise co-
peptin level and Dcopeptin revealed to be an indica-
tor for detection of ischemia on perfusion images.
Another aim of our study was to differentiate 
patients with normal and equivocal MPS results. 
Equivocal test results are frequently encountered 
in clinical practice and can lead physician to apply 
further non-invasive and invasive diagnostic tests. 
Although several technical and patient related 
interventions have been introduced to handle this 
problem, but none of them has ability to solve the 
problem totally [5–8]. Here, we introduced another 
aspect of copeptin use. We found that patients with 
equivocal perfusion images had similar pattern of 
serum copeptin changes in response to exercise. 
In other words, detection of post-exercise copeptin 
level reduction into pre-exercise level may be help-
ful sign to interpret equivocal perfusion images as 
normal MPS result.
Neither adenosine nor dipyridamole was used 
to induce coronary ischemia, Instead, we used 
ETT. Adenosine based MPS was proven to have 
higher diagnostic ability than dipyridamole based 
protocols, however it had equal diagnostic ability 
compared to exercise based protocols [24, 25]. 
Thus, to obtain measurable and similar level of 
physical stress, we applied ETT to induce coronary 
ischemia.
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Limitations of the study
Number of subjects with ischemia on MPS 
was low, thus we could not perform any further 
analysis for relation between extent of myocardial 
ischemia and post-exercise copeptin increment. 
Failure to exclude possible presence of CAD in all 
patients with equivocal MPS was another limita-
tion to the study.
Conclusions
Copeptin is a rapidly detected biomarker, it 
can be detected in the circulation even before tro-
ponin becomes positive. It increases in presence 
of acute myocardial infarction, heart failure, shock, 
and endogenous stress. Here, we have proven that 
patients with normal and equivocal MPS results 
had similar pattern of copeptin changes in response 
to exercise, while patients with ischemia on MPS 
had higher level of post-exercise copeptin and 
Dcopeptin levels. Copeptin may be helpful both to 
detect ischemia and to differentiate equivocal test 
results on MPS.
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